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Abstract: The goal to attenuate inflammation without inducing generalized immunosuppression has focused the attention
on chemokines, a family of chemotactic peptides that regulate the leukocyte traffick into tissues. However, the
development of drugs that block ckemokine activity may be hampered by the observation that some chemokines display
pleiotropic biologic functions. For example, the chemokines CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC exhibit
the ability to recruit different leukocytes subsets, the capacity to induce the proliferation of vascular pericytes as well as
powerful anti-tumor effects, which are mediated by a common receptor, named CXCR3. Because of their pleiotropic
biologic effects, these chemokines have been proposed as possible therapeutic targets in cancer, allograft rejection,
glomerulonephritis, diabetes, multiple sclerosis, and autoimmune disorders of the thyroid. The chemokine CXCL4/PF4
shares several activities with CXCL9, CXCL10, and CXCL11, including angiostatic effects, although its specific receptor
has remained unknown for a long time. Recently, we provided evidence that the different functions of CXCL9, CXCL10,
and CXCL11 on distinct cell types can be at least partly explained by the interaction of these chemokines with two distinct
receptors. Indeed, in addition to the classic form of CXCR3 receptor, which we have renamed as CXCR3-A, a novel
CXCR3 receptor variant (CXCR3-B) was identified, that not only mediates the angiostatic activity of CXCR3 ligands, but
also acts as functional receptor for CXCL4.
In this review, we focus on the accumulating evidence demonstrating the pivotal role of CXCR3-binding chemokines in
several human diseases. Studies based on CXCR3 targeting have shown its importance in different pathologic conditions
and orally active small molecules capable of inhibiting this receptor are now being developed in order to be tested for their
activity in humans.
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INTRODUCTION
Chemokines are a family of small, structurally related,
molecules that regulate cell trafficking of various subsets of
leukocytes [1-3] and are distinguishable from other cytokines
because they are the only members of the cytokine family
that act on the superfamily of G-protein-coupled serpentine
receptors. Even though these properties still define their
nature, other important functions of chemokines have been
discovered, including regulation of embryonic development
[4], pathophysiology of the central nervous system [5],
wound healing repair [6], control of angiogenesis [7] and
tumor growth and spread [8]. The nomenclature for
chemokines is based on the configuration of a conserved
amino-proximal cysteine-containing motif. Based on this
system, there are currently four groups of molecules in the
chemokine family: CXC, CC, CX3C, and C (where X is any
amino acid). Chemokines were initially named according to
their function or on the basis of the cell type that produced
them, giving rise to redundant names for the same
chemokine sequence. In order to eliminate such a confusion,
a systematic nomenclature has recently been adopted (Table
1) [1].
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CXCR3-BINDING CHEMOKINES EXHIBIT UNIQUE,
PLEIOTROPIC BIOLOGIC FUNCTIONS
The CXC chemokine subfamily includes fourteen
different members, whose encoding genes are clustered on
human chromosome 4, with the exception of SDF-
1/CXCL12, which is mapped to 10q11.21, BRAK/CXCL14,
which is mapped to 5q31.1, and CXCL16, which is mapped
to 17q13. [5]. Most members of the CXC chemokine family
exhibit chemotactic properties toward neutrophils and
lymphocytes, and act as positive or negative regulators of
angiogenesis. The angiostatic members of the CXC
chemokine family include IP-10/CXCL10, MIG/CXCL9, I-
TAC/CXCL11 and PF-4/CXCL4 [3-7]. These chemokines
induce injury on established tumor-associated vasculature
and promote extensive tumor necrosis [3-7] and, therefore,
they have been proposed as useful therapeutic agents in
cancer [4]. The angiostatic effects of CXCL9, CXCL10, and
CXCL11 on human microvascular endothelial cells
(HMVEC) are mediated by the CXC chemokine receptor 3
(CXCR3) [9, 10], whereas the receptor for CXCL4 has
remained unknown for a long time [4]. Several studies have
pointed out that CXCL10 and CXCL4 share a great number
of activities, such as the inhibition of chemotaxis and the
proliferation of endothelial cells [11], or the inhibition of
hematopoiesis [12]. However, the interaction of CXCL9,
CXCL10, and CXCL11 with CXCR3 also results in the
chemotaxis of activated type-1 T helper (Th1) cells, natural
killer (NK) cells, macrophages, and dendritic cells [13-17],
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CXCL1 4q12-ql3 GRO-α CXCR2>CXCR1
CXCL2 4q12-ql3 GRO-β CXCR2
CXCL3 4q12-ql3 GRO-γ CXCR2
CXCL4 4q12-ql3 PF4 CXCR3 - B>>>>CXCR3 - A
CXCL5 4q12-ql3 ENA-78 CXCR2
CXCL6 4q12-ql3 GCP-2 CXCRl/CXCR2
CXCL7 4q12-ql3 NAP-2 CXCR2
CXCL8 4q12-ql3 IL.-8 CXCR1, CXCR2
CXCL9 4q21.21 Mig CXCR3-A/CXCR3-B
CXCL10 4q21.21 IP-10 CXCR3-A/CXCR3-B
CXCL11 4q21.21 I-TAC CXCR3-A/CXCR3-B
CXCL12 10q11.1 SDF-lα/β CXCR4
CXCL13 4q21 BLC/BCA-l CXCR5
CXCL14 5q31.1 BRAK unknown
CXCL15 unknown Lungkina/WECHE unknown
CXCL16 17ql3 CXCR6
C CHEMOKINES
XCL1 1q23 Lymphotactin XCR1
XCL2 1q23 SCM-13 XCR1
CX3C CHEMOKINES
CX3CL1 16q13 Fractalkine CX3CR1
CC CHEMOKINES
CCL1 17q11.2 I-309 CCR8
CCL2 17q11.2 MCP-1 CCR2, CCR11
CCL3 17q11.2 MIP-1α CCR1, CCR5
CCL4 17q11.2 MIP-1β CCR5
CCL5 17q11.2 RANTES CCR1, CCR3, CCR5
CCL6 unknown C10/MRP-1 unknown
CCL7 17q11.2 MCP-3 CCR1, CCR2, CCR3, CCR11
CCL8 17q11.2 MCP-2 CCR3, CCR11
CCL9/10 unknown MIP-1γ unknown
CCL11 17q11.2 eotaxin CCR3







CCL12 unknown MCP-5 CCR2
CCL13 17q11.2 MCP-4 CCR2, CCR3, CCR11
CCL14 17q11.2 HCC-1 CCR1
CCL15 17q11.2 HCC-2 CCR1, CCR3
CCL16 17q11.2 LEC CCR1, CCR8
CCL17 16q13 TARC CCR4
CCL18 17q11.2 PARC unknown
CCL19 9p13 ELC CCR7, CCR10
CCL20 2q33-q37 LARC CCR6
CCL21 9p13 SLC CCR7, CCR10
CCL22 16q13 MDC CCR4
CCL23 17q11.2 MPIF-1 CCR1
CCL24 7q11.23 eoTaxin-2 CCR3
CCL25 19p13.2 TECK CCR9
CCL26 7q11.23 eoTaxin-3 CCR3
CCL27 9p13 CTACK CCR10
CCL28 5p12 MEC CCR3/CCR10
while CXCL4 chemotactic properties are less pronounced
and much more controversial [18,19]. Furthermore, CXCL9
and CXCL10 induce increased survival and growth of
several types of human vascular pericytes recruitment their
receptor CXCR3 [20-22]. Thus, the apparently opposite
effects of CXCR3-binding chemokines on HMVEC and on
vascular pericytes allowed us to hypothesize the existence of
cell-specific signal transduction pathways and/or distinct
CXCR3 receptor variants. Accordingly, recent results
obtained in our laboratory [23] have identified a novel
mRNA generated by an alternative splice site within the
intron of the CXCR3 gene by using rapid amplification of
cDNA ends (RACE) and Northern blot analysis. Real Time
Quantitative RT-PCR and transfection of the HMVEC line
HMEC-1 provided evidence for the existence of a previously
unrecognized receptor, named CXCR3-B, which mediated
the inhibitory activity of CXCL9, CXCL10, and CXCL11 on
the growth of HMVEC. Binding assay and signal
transduction analysis demonstrated that CXCR3-B also acts
as a functional receptor for CXCL4, thus explaining the large
overlap between the biological activities of CXCL10 and
CXCL4 and their potent angiostatic effect. By contrast, the
classic CXCR3 receptor, re-named as CXCR3-A, mediates
the proliferation of vascular pericytes [23]. In this review, we
will focus on the possible role of CXCR3-binding
chemokines in those diseases for which many converging
results are now available.
CXCR3-BINDING CHEMOKINES IN CANCER
BIOLOGY
In the early 1990, CXCL10 was reported to elicit a host-
mediated and T cell-dependent antitumor effect against a
murine plasmacytoma and mammary adenocarcinoma [24].
Accordingly, CXCL9 and CXCL10 mediate chemotaxis of
activated T cells, NK cells, dendritic cells and γδ cells, thus
targeting all the components of the anti-tumor immune
response [13-17]. However, CXCL10 appears to exert
antitumor effect also independently of T and B-cell
immunity, because it was also active in SCID mice [25-27].
Although NK cells recruited by CXCL9 and CXCL10 can be
responsible for tumor regression in SCID mice [28],
CXCL10 induces injury on established tumor-associated
vasculature with intravascular thrombosis and extensive
tumor necrosis [25-27]. In a similar way, CXCL9-treated
tumors displayed central and homogeneous necrosis, as one
might expect from insufficient tumor blood perfusion, and
generalized evidence of vascular damage [28,29].
Furthermore, CXCL10  expression by human lung tumors in
SCID mice was associated with reduced tumor growth
potential, while neutralization of CXCL10 enhances growth,
and overexpression of CXCL9 resulted in the inhibition of
non small cell lung cancer tumor growth and metastasis via a
decrease in tumor-derived vessel density [28]. Many studies
also support a critical role for CXCL10 and CXCL9 in
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mediating the antitumor effect of IL-12 [30-34]. Another
chemokine exerting powerful anti-tumor properties in SCID
mice models is CXCL4 [35-40]. CXCL4 displays anti-
angiogenic activity in vivo and can inhibit the growth of
tumors without exerting relevant activity in the recruitment
of inflammatory cells [39,40]. CXCL4 inhibits angiogenesis
through different concomitant mechanisms. Because of their
heparin-binding motifs, both CXCL4 and CXCL10 have
been shown to interfere with the binding of fibroblast growth
factor (FGF)-2 or vascular endothelial growth factor
(VEGF)165 to their receptors (i) by imparing the growth
factor’s ability to form homodimers, (ii) competing with
heparan sulfate proteoglycans on the cell surface, or (iii)
directly binding to these growth factors [41,42]. However, a
large body of evidence also indicates that CXCL4 could
deliver its specific inhibitory signal through a not yet
identified specific receptor that, like CXCR3-B [9], is
expressed by HMVECs only when they proliferate [43-45].
The discovery of CXCR3-B as the first high affinity
functional receptor for CXCL4, and as a common receptor
for the four angiostatic chemokines shed a new light on this
controversial problem. CXCL4 showed a strong anti-tumor
activity in in vivo  models of breast cancer, melanoma, colon
carcinoma, osteosarcoma, ovarian cell carcinoma and glioma
[35-40]. Some studies however, also proposed a concomitant
direct inhibitory effect on the growth of carcinoma cells [46,
47, 23].
CXCR3-BINDING CHEMOKINES IN ENGRAFTMENT
AND ALLOGRAFT SURVIVAL
Despite the administration of immunosuppressants,
allograft rejection remains the primary cause of human renal
transplant failure. Acute rejection (AR) is particularly
frequent in the early post-transplant period and, despite the
graft loss in only a small percentage of subjects, it represents
a leading cause of morbility and hospitalization, and
predisposes renal allografts to the development of chronic
rejection (CR) [48]. Cardiac allograft recipients lacking
CXCR3 have a profound delay in development of allograft
rejection [49]. Consistent with this study, targeting of
CXCL10 production by endothelial cells from a transplant,
which was demonstrated using cardiac grafts from CXCL
10 donors [50], also remarkably prolonged graft survival. A
concomitant treatment with a subtherapeutic dose of
cyclosporine A (CsA), led to permanent allograft survival in
CXCR3-/- recipients [51]. Therapy with an anti-CXCR3 mAb
can prevent graft recruitment of activated T cells and reverse
the development of acute allograft rejection in rodent models
[49]. The value of targeting donor-derived CXCL10
production was also shown in a heterotopic small bowel
allograft model [51]. Hence, local upregulation of CXCL10
lead to the initial activation of CXCR3+ NK cells and release
of interferon (IFN)-γ by these cells, followed by further
upregulation of CXCL10 and production of additional
chemokines. The allo-response is then progressively
amplified through the recruitment of CXCR3+ T helper (Th)-
1 cells and other effector cells, especially macrophages. In
contrast to blocking monoclonal antibodies (mAbs),
antisense therapy directed at CXCR3 [52], or blockade of
chemokine binding to local glycosaminoglycans [53], has
proven to be modestly effective. There is now a rapidly
developing literature on the expression of chemokines and
their receptors in human allografts [54]. Of relevance, the
intragraft expression of CXCR3 and its ligands has been
reported in association with clinical rejection of renal [55],
lung [56], and cardiac [57-60] allografts. In the unique on
renal allograft study, induction of CXCR3 and CXCL10
mRNA was associated with acute rejection [56]. In the
considerably larger lung study [57], immunohistological
analyses showed that areas characterized by acute cellular
rejection (grades 1–4) and active obliterative bronchiolitis
(chronic rejection) were infiltrated by CXCR3+ T cells, and
high levels of CXCR3 ligands were found within
bronchoalveolar lavage fluids of patients with rejection
episodes. Furthermore, in 169 sequential endomyocardial
biopsies from clinical cardiac allograft recipients [57], the
expression of CXCR3 and its ligand CXCL10 was
temporally and spatially associated with CD3+ T cell
infiltrates, and correlated with the histopathological
diagnosis of acute rejection. Persistent expression of CD3+
and CXCR3+ infiltrating cells was seen in biopsies from four
out of seven patients followed for one year, who developed
intimal thickening, as shown by intravascular ultrasound.
Indeed, CXCR3 chemokines not only attract leukocytes, but
also alter the functions of vascular wall cells [23]. The dual
targets of CXCR3 chemokines on immune and vascular cells
suggest an important role for this group of cytokines in
chronic rejection and allograft arteriosclerosis, a disease
characterized by immune-mediated vascular smooth muscle
cell proliferation. Data linking intragraft expression of
CXCR3 and its ligands with development of acute and
chronic cardiac allograft rejection were recently also
reported by other groups [57-59]. In addition, elevated levels
of the CXCR3 ligand, CXCL11, were associated with the
development of coronary artery transplant vasculopathy [60],
whereas serum levels of MCP-1/CCL2, although raised,
were not [61]. A recent study provided the first direct
evidence that persistent elevation of CXCL10 and CXCL11
in human cardiac allografts is associated with the
development of chronic rejection. CXCR3 chemokines most
likely recruit T cells to transplanted hearts, and also alter
vascular EC and smooth muscle cell (SMC) functions. Both
processes can promote the development of chronic allograft
vasculopathy (CAV). Very recently, we demonstrated that
CXCL10, CXCL9, CXCL11 and CXCL4, as well as both the
receptor variants CXCR3-A and CXCR3-B, are highly
expressed in the kidney of subjects suffering from either AR
or CR (Lazzeri E. et al. submitted). As hypothesized,
CXCR3-B was highly expressed by endothelial cells of
damaged vascular structures, thus suggesting its contribution
to EC necrosis. Surprisingly however, CXCR3-B was also
widely expressed at level of tubular structures in both AR
and CR. The expression of CXCR3-B was also confirmed, at
both mRNA and protein level, by primary cultures of renal
proximal tubular epithelial cells. Surface expression of
CXCR3-B was linked to the S-phase of the cell cycle and
mediated growth inhibition of epithelial cells, suggesting that
CXCR3-B expression might contribute not only to chronic
EC injury, but also to interstitial damage and tubular atrophy
during AR and CAN (Lazzeri E. et al. submitted). Finally,
the demonstration that pretransplant serum CXCL10 levels
in patients with end stage renal disease undergoing chronic
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dialytic treatment are a clinically useful parameter for the
identification of subjects exhibiting high risk of graft failure
(Rotondi M. et al. submitted) suggests that these subjects
may require heavier postransplant immunosuppressive
regimens.
CXCR3-BINDING CHEMOKINES IN PROLIFERA-
TIVE GLOMERULONEPHRITIS
The proliferation of resident mesangial cells and the
expansion of mesangial matrix, accompanied by elicitation
of lymphocytes and monocytes from the circulation into the
inflammed tissue, are prominent features of many types of
immunologically mediated GN that, in agreement with these
important pathologic alterations, are named proliferative
glomerulonephritis (PGN). PGN are socially important
diseases, inasmuch as IgA nephropathy is presently the most
frequent kind of acute nephritis throughout the world [62].
Recent reports have focused attention on the relationship
between inflammatory nephropaties and chemokines [63,64].
CXCL10 was found to be produced by mesangial cells
(MC), and the kidney appears to be the most important
source of this chemokine in response to IFN-γ stimulation
[65]. Recently, we have reported high expression of CXCL9
and CXCL10 by resident glomerular cells and of their
receptor, CXCR3, in MC of patients with proliferative GN
[66,20]. Moreover, CXCR3 was also found on the surface of
cultured human MC (HMC), and appeared to mediate both
intracellular Ca2+ influx and cell proliferation [20].
Furthermore, it was found that in both HMC and other types
of vascular pericytes, CXCL10 and CXCL9 also induce
chemotaxis and CXCR3 triggering results in Src activation,
which in turn leads to the recruitment of Ras and activation
of the ERK cascade [21]. In parallel, activation of PI 3-K and
Akt can also be observed [21]. Taken all together, these
findings may account for at least some mechanisms involved
in the pathogenesis of proliferative GN. It is indeed
reasonable to speculate that the initial event, such as
deposition of immune complexes, interactions of IgA
immunoglobulins with their Fc receptors expressed on HMC,
or other insults, may induce both CXCL9 and CXCL10
production by resident glomerular cells [66], thus favoring
the transmigration of Th1 cells and macrophages through the
activation of adhesion molecules. Accordingly, Th1 effectors
have been observed in the glomeruli of patients affected by
severe proliferative GN, as well as in the glomeruli of
patients affected by active forms of IgA nephropathy [67].
Activated Th1 cells and macrophages are able to produce
IFN-γ and TNF-α, which in turn can amplify both CXCL10
and CXCL9 production. Interestingly, the administration of
IFN-γ before the stimulation of mesangial cell (MC) with
PDGF or EGF dramatically increases their proliferation,
suggesting a possible pathogenic role of Th1 cells recruited
by CXCL10 and CXCL9 glomerular expression in the early
phase of proliferative GN [68]. Whether the same initial
insult that induces CXCL10 and CXCL9 production and
consequently the recruitment of Th1 cells and macrophages
is also responsible for the up-regulation of CXCR3
expression by MC in the same kidneys is presently unclear.
However, the interaction of CXCL10 and CXCL9 with their
receptor expressed by MC can account for chronic
stimulation of their proliferation and, therefore, the
production of these chemokines allows to explain multiple
aspects of the inflammatory reaction characteristic of
proliferative GN.
CXCR3-BINDING CHEMOKINES IN DIABETES
Insulin-dependent (type 1) diabetes mellitus (IDDM) is a
T cell–driven autoimmune disease of unknown etiology that
results in the destruction of the islets of Langerhans in
predisposed individuals. The mechanisms by which antigen-
specific T cells migrate to the islets—a prerequisite for the
specific lysis of β cells—is largely unknown. Given the
absence of knowledge on the etiologic agent of IDDM,
delineating the process of T-cell infiltration provides a basis
for understanding the development of this autoimmune
disease. A recent study demonstrated that during insulitis,
the β cell itself synthesizes and secretes CXCL9 and
CXCL10, which are the driving force for the accumulation
of the CXCR3+ cytotoxic T cells [69]. Thus, β cells, the
target of autoimmunity in IDDM, are largely responsible for
attracting islet-specific cytotoxic T cells and thus facilitate
their own demise. High IFN-γ concentration in β islets
correlated with both substantial expression of CXCL9,
CXCL10 and CXCR3 and prominent infiltration of T cells.
IFN- γ was necessary and sufficient to stimulate CXCL9 and
CXCL10 expression in cells, as the selective exposure of
these cells to IFN-γ was sufficient to induce the expression
of both chemokines. Taken together, these data suggest that
the pathology of islet invasion represents an inflammatory
loop effected by T cell–derived IFN-γ, which first induces
CXCL10/CXCL9 in β cells, leading to heightened
immigration of additional IFN-γ-secreting T cells, that is in
turn mediated by CXCR3 [69,70]. The significant role of
CXCR3 in the immunopathogenesis of IDDM was directly
demonstrated in a model of IDDM transgenic mice crossed
with mice deficient for CXCR3. At day 8 after infection,
islets of singly transgenic mice demonstrated severe T-cell
infiltration and islet destruction. In contrast, the islets of
transgenic CXCR3-deficient mice were not invaded,
although T cells adorned their rim. In addition, monitoring
blood glucose levels revealed a significant delay in the
occurrence of diabetes in transgenic mice, which had been
made deficient for CXCR3. These observations demonstrate
the critical importance of CXCR3 over other inflammatory
chemokine receptors in the pathogenesis of IDDM Fig. (1).
Some data on the role of CXCL10 in the pathogenesis of
IDDM are also available in human beings. IFN-γ and
CXCL10 were quantified by solid-phase ELISA in the sera
of patients with either newly diagnosed or long-term IDDM,
as well as in the sera of their healthy first degree relatives.
The latter were subdivided into "low" and "high" risk
prediabetic subjects, depending on whether they were
negative or positive for the anti islet cell antibodies (ICA)
and glutamic acid decarboxylase antibodies (GAD).
Compared with healthy control subjects, those with a low
risk of disease and the group of patients with long-term
IDDM, CXCL10 was found more frequently and at increased
concentrations in both newly diagnosed IDDM patients and
in those with a high risk of disease; in the latter, the CXCL10
concentrations correlated with levels of IFN-γ [71-73]. The
results of these studies demonstrate that circulating CXCL10
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concentrations are increased in patients with IDDM, but only
during the early and subclinical stage of the disease.
However, given the large prevalence of female subjects in all
these studies among the groups of newly diagnosed IDDM
patients compared to controls, these results have been
questioned. Indeed, in a recent study performed in a larger
number of patients, where controls and newly diagnosed
IDDM patients were exactly sex-matched, this observation
was not confirmed, while higher CXCL10 levels were
observed among female subjects when compared to males
[70, 74]. This finding might be related to the well known
high prevalence among young women of subclinical
autoimmune thyroid disorders, a condition that was
associated with high CXCL10 serum levels even in patients
groups containing comparable numbers of men and women
[70,75].
CXCR3-BINDING CHEMOKINES IN MULTIPLE
SCLEROSIS
Multiple sclerosis (MS) is an autoimmune disease
associated with a Th1 cell predominance phenotype. It is
therefore believed that activated T cells have a crucial role.
Chemokine receptors have been shown to be highly
expressed in brain samples from MS patients after autopsy
[76-78]. One of these receptors, CXCR3, is expressed by
activated T cells, so it might be responsible for the
recruitment of auto-aggressive T cells. This hypothesis was
further supported by the demonstration of high levels of the
CXCR3 ligand CXCL10 in these lesion samples.
Cerebrospinal fluid (CSF) levels of CXCL9 and CXCL10
were significantly elevated in MS patients, and there was a
positive correlation between the concentration of CXCL10
and CSF cell count. Other  chemokines that act on monocytes
and T cells, including MIP-1α/CCL3, MIP-1β/CCL4, and
MCP-1/CCL2, were either undetectable or modestly reduced
during MS attacks [78]. More importantly, CXCR3 was the
predominant chemokine receptor on lymphocytic cells in
both CSF and parenchymal compartments. These findings
support the possibility that activated T cells expressing
CXCR3 preferentially gain access to central nervous system
(CNS) tissues during the formation of acute MS lesions.
Accordingly, 80% of CD4+ cells in MS CSF expressed
CXCR3, suggesting that these receptor-bearing cells play an
important role in MS pathogenesis. The functional relevance
of elevated CSF CXCL10 and CXCL9 levels in MS was
further supported by the uniform detection of CXCR3-
positive cells in perivascular inflammatory cuffs in MS brain
sections [76-78]. The accumulation of these cells was
directly correlated with lesions in which demyelination
occurs, followed by axonal loss, which ultimately leads to
paralysis. These data are consistent with previous reports
showing that anti–CXCL10 antibodies abolished chemotactic
activity toward T-cell blasts in the CSF of patients with
Fig. (1). Proposed mechanism of lymphocyte recruitment during the early phases of IDDM leading to insulitis and β-cell destruction.
β cells, the target of autoimmunity in IDDM, synthesize and secrete CXCL9 and CXCL10 and are largely responsible for attracting islet-
specific CXCR3+ cytotoxic T cells, thus facilitating their own demise. The recruitment of Th1 cells and macrophages leads to amplification
and persistence of the inflammatory response.
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meningitis [79]. The demyelination process that occurs in the
central nervous system (CNS) of patients with MS is due, in
part, to an inflammatory response in which CD4+ and CD8+
T cells and macrophages infiltrate white matter. While it is
thought that the inflammatory and demyelination process in
MS is the product of Th1-associated cytokines secreted by
myelin protein-specific CD4+ T cells present in the CNS, the
mechanisms responsible for the recruitment and maintenance
of these myelin-reactive CD4+ T cells in the CNS have not
yet been elucidated. In a recent study, it was demonstrated
that the majority of the chemotactic activity toward CD4+ T
cells specific for a myelin basic protein peptide is mediated
by CXCL10 [80] Fig. (2).
CXCR3-BINDING CHEMOKINES IN AUTOIMMUNE
THYROID DISORDERS
Thyroid glands affected by autoimmune disorders show
striking lymphocytic infiltration, mainly composed by T
cells [81]. The mechanisms by which the different
lymphocytic subsets are recruited and arrested in the thyroid
tissue are unknown. Recent studies provided evidence that
the chemokines CXCL10 and CXCL9, as well as their
common receptor, CXCR3, are present in human tissue
specimens obtained from patients affected by thyroid
autoimmune disorders [75,82,83]. Thyroids from both
patients with Graves’ disease (GD) or Hashimoto’s
thyroidites (HT) expressed higher levels of CXCL10,
CXCL9 and CXCR3, if compared not only with normal
thyroids, but also with toxic adenoma (TA), a
nonautoimmune thyroid disorder [75,82,83]. Interestingly, as
previously described in papillary carcinoma of the thyroid
[84], resident epithelial follicular cells expressed CXCL10
and CXCL9 mRNA and protein, suggesting a possible role
for the inflammed thyroid epithelium in the recruitment of
infiltrating lymphocytes. Finally, a significant inverse
correlation was observed between serum levels of CXCL10
and GD but not HT disease duration [75] .
Taken together, these data suggest a possible pathogenic
role of chemokines CXCL10 and CXCL9 in the initiation of
autoimmune thyroid disorders and provide additional
evidence to the view that Th1-dominated responses, or at
least the production of IFN-γ and TNF-α, may play an
important pathogenic role in the initial events of the
inflammatory process in these diseases [75,82,83]. On the
other hand, the finding that CXCL10 production declines at
level of both thyroid gland and serum in GD, but not in HT
patients in the later phases of these disorders, may be
consistent with the results of another study suggesting a
progressive switch from Th1- to Th2-polarized profile in the
course of GD but not in HT [85]. This shift probably reflects
a counter regulatory mechanism against inflammation, which
has been observed even in other diseases [86,87]. Previous
studies [88] demonstrated that GD thyrocytes expressed
CD95 and CD95L in a similar manner to HT thyrocytes, but
Fig. (2). Proposed mechanism of lymphocyte recruitment during the early phases of MS leading to demyelination. MS is an
autoimmune disease associated with a T-helper type 1 phenotype. The recruitment of circulating auto-aggressive CXCR3 positive Th1 cells
from peripheral vessels, leading to demyelination and then axonal loss, is mediated through brain production of CXCL9, CXCL10 and
CXCL11.
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did not undergo CD95-induced apoptosis, due to the
differential role of Th1 and Th2 cytokines. Indeed, IFN-γ
promoted caspase upregulation and CD95-induced apoptosis
in HT thyrocytes, whereas IL-4 and IL-10 protected GD
thyrocytes by potent up-regulation of cFLIP and Bcl-XL,
which prevented CD95-induced apoptosis in sensitized
thyrocytes. Thus, modulation of apoptosis-related proteins
by Th1 and Th2 cytokines control thyrocyte survival in
thyroid autoimmune disorders [89]. Finally, the finding that
the CXCR3-binding chemokines are not only produced by
infiltrating T cells and macrophages, but also by resident
follicular epithelial cells themselves, suggests that these
latter may play a previously unrecognized role in the
recruitment of infiltrating cells and therefore in the triggering
of thyroid gland inflammation. However, the stimulatory
agents (viral infections?) that may enable thyrocytes to
produce CXCL10 and CXCL9 in the initial stages of
autoimmune thyroid disorders are still unknown.
CONCLUSIONS
Since the discovery of the chemokine family the strategy
of selectively blocking the leukocyte recruitment to the site
of inflammation has been validated by several approaches.
Indeed, despite redundancy reported by studies in vitro on
ligand–receptor binding and activation, in vivo the system
acts through a coordinated and perhaps sequential chain of
events, with temporal and spatial control mechanisms
coming into play. Thus, interfering with an essential link in
the chain, such as CXCR3 in the case of some autoimmune
disorders or organ allograft transplant or diabetes might
result in a total inhibition of the inflammatory process, as
demonstrated in CXCR3-/- models. Furthermore, the recent
discovery of distinct receptors generated by alternative
splicing of the CXCR3 gene would allow to obtain selective
inhibitors of the two receptors, thus limiting undesired side
effects. Otherwise a combined activation of the two receptors
might be useful in some clinical conditions, such as cancer,
where both enhancement of the immune response and
inhibitory effects on angiogenesis and tumor cell growth are
useful. We look forward to new types of experimental
studies, since active orally available small molecule
inhibitors of CXCR3 are now being developed.
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ABBREVIATIONS
SDF-1 = Stromal-derived factor-1
BRAK = Breast and kidney-expressed chemokine
SR-PSOX = Scavenger receptor that binds
phosphatidylserine and oxidized
lipoprotein
IP-10 = IFN-inducible protein-10
MIG = Monokine induced by interferon (IFN)-
gamma
I-TAC = Interferon-inducible T-cell alpha
chemoattractant)
PF-4 = Platelet factor four
HMVEC = Human microvascular endothelial cells
Th1 = Type-1 T helper cell
NK = Natural killer
RACE = Rapid amplification of cDNA ends
HMEC-1 = Human microvascular endothelial
SCID = Severe combined immunodeficiencies
FGF-2 = Fibroblast growth factor 2
VEGF165 = Vascular endothelial growth factor
AR = Acute rejection
CR = Chronic rejection
CsA = Cyclosporine A
(IFN)-γ = Interferon-γ
mAbs = Monoclonal antibodies
MCP-1 = Monocyte chemoattractant protein 1
EC = Endothelial cell
SMC = Smooth muscle cell
CAV = Chronic allograft vasculopathy
GN = Glomerulonephritis
PGN = Proliferative glomerulonephritis
HMC = Human mesangial cell
TNF-α = Tumor necrosis factor-alpha
PDGF = Platelet-derived growth factor
EGF = Epidermal growth factor
IDDM = Insulin-dependent (type 1) diabetes
mellitus
ICA = Islet cell antibodies
GAD = Glutamic acid decarboxilase antibodies
MS = Multiple sclerosis
CSF = Cerebrospinal fluid
MIP-1α = Macrophage inflammatory protein-1α
MIP-1ß = Macrophage inflammatory protein-1
MCP-1 = Monocyte chemoattractant protein 1
CNS = Central nervous system
GD = Graves’ disease
HT = Hashimoto’s thyroidites
TA = Toxic adenoma
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